



Global Wellness Brand KaleidoMyco Prepares to Go Public Global Wellness Signs as Exclusive Corporate Advisor

Vancouver, British Columbia, August 15, 2022 – **Global Wellness Strategies Inc. (CSE: GWS) (Frankfurt: O3X4) (OTCQB: GWSFF) (“Global” or the “Company”)** is pleased to announce that their brand KaleidoMyco, LLC (“KM”) is in the process of preparing a listing statement to a public exchange.

Global Wellness Strategies is assisting KaleidoMyco prepare the listing statement to be filed to a regulated public exchange and has been engaged as the exclusive corporate advisor. While it is the intention of KM to list their shares as soon as possible; they will be required to meet all regulatory and listing requirements before trading commences in their shares. A financing will accompany their public listing statement.

About KaleidoMyco : CBD Infused Medicinal Mushroom Products: 1 + 1

Medicinal aka functional mushrooms are increasingly relevant, much like CBD, because of their ancient healing powers on an array of modern-day ailments. Taking these two powerful plant medicines together enables one to experience enhanced effects. The synergistic combination of both hemp- derived CBD and medicinal mushrooms is amazing. Immunity boost, increased cognitive focus, and balanced energy are benefits of medicinal mushrooms. While hemp CBD benefits can include decreased anxiety, reduced pain and improved sleep.

KaleidoMyco has developed the first-ever dissolvable cannabidiol infused myco tablets to enter the effervescent category. The tablets dissolve quickly in a glass of water, adding effervescence and flavor, and are an excellent way to supplement a healthy diet with an array of complementary and synergistic ingredients. Their next 2 myco-dosing products are powder infused pills and CBD myco one shots. KM hopes to file a formula patent in Canada.

GWS Corporate Comment:

On April 5, 2021, and subsequently, on September 24, 2021, the Company entered into a Limited Liability Company Membership Interest Purchase Agreement and an Agreement Amendment (collectively the “Agreement”) with KM, a private Florida, United States company, whereby the Company would purchase all the membership interest in KaleidoMyco in one (1) tranche representing a 51% membership interest and the second (2) tranche representing a 49% membership interest. The assets in KM include researched formulas related to KaleidoMyco potential product line. At the present time the Company has a 51% of membership interest in KM.

“For us, the process of going public for KaleidoMyco is just the beginning of a new journey, as we accelerate our efforts to help our brands turn insights into action and leverage the resources of the public markets to enter their next phase of organic growth. We are moving forward with our partner Shanti Therapeutics in preparation for their MDMA clinical trials and focusing our energy on becoming the leader in MDMA pain solutions and a pure play bio-pharma company.” Said Meris Kott, CEO Global Wellness Strategies Inc.

About Global Wellness Strategies:

Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies.

For further information visit websites:

www.globalwellnessstrategies.com

Or Contact Meris Kott CEO 604.484.0355 or email to info@globalwellnessstrategies.com

Further information about the Company is available on www.SEDAR.com under the Company’s profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward-looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.